Lv22
150 积分 2024-09-05 加入
Obinutuzumab in Refractory Membranous Nephropathy: A Case Series
2小时前
已完结
Obinutuzumab in untreated primary membranous nephropathy: An observational case series
1天前
已完结
Mapping antigens of membranous nephropathy: almost there
1个月前
已完结
Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis
1个月前
已完结
Obinutuzumab for PLA2R-associated membranous nephropathy
2个月前
已关闭
An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells
3个月前
已完结
Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies
3个月前
已完结
Obinutuzumab is Effective as an Initial Treatment for PLA2R-Associated Primary Membranous Nephropathy: A Retrospective, Single-Center Trial
3个月前
已关闭
MAJESTY: A Phase 3, Randomized, Open-Label, Active Comparator-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy
4个月前
已关闭
Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy
5个月前
已完结
皖公网安备34019202002308
